- Home
- ACOG vs ANL Comparison
ACOG vs ANL Comparison
Compare ACOG & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACOG
- ANL
- Stock Information
- Founded
- ACOG 2000
- ANL 2004
- Country
- ACOG Canada
- ANL Cayman Islands
- Employees
- ACOG N/A
- ANL N/A
- Industry
- ACOG
- ANL
- Sector
- ACOG
- ANL
- Exchange
- ACOG Nasdaq
- ANL Nasdaq
- Market Cap
- ACOG 80.3M
- ANL 73.8M
- IPO Year
- ACOG N/A
- ANL 2023
- Fundamental
- Price
- ACOG $9.74
- ANL $1.59
- Analyst Decision
- ACOG Strong Buy
- ANL Buy
- Analyst Count
- ACOG 1
- ANL 2
- Target Price
- ACOG $20.00
- ANL N/A
- AVG Volume (30 Days)
- ACOG 196.9K
- ANL 11.0K
- Earning Date
- ACOG 05-15-2025
- ANL 06-13-2025
- Dividend Yield
- ACOG N/A
- ANL N/A
- EPS Growth
- ACOG N/A
- ANL N/A
- EPS
- ACOG N/A
- ANL N/A
- Revenue
- ACOG $2,928,654.00
- ANL N/A
- Revenue This Year
- ACOG N/A
- ANL N/A
- Revenue Next Year
- ACOG N/A
- ANL N/A
- P/E Ratio
- ACOG N/A
- ANL N/A
- Revenue Growth
- ACOG N/A
- ANL N/A
- 52 Week Low
- ACOG $3.75
- ANL $1.10
- 52 Week High
- ACOG $11.40
- ANL $8.24
- Technical
- Relative Strength Index (RSI)
- ACOG N/A
- ANL 42.48
- Support Level
- ACOG N/A
- ANL $1.71
- Resistance Level
- ACOG N/A
- ANL $2.10
- Average True Range (ATR)
- ACOG 0.00
- ANL 0.08
- MACD
- ACOG 0.00
- ANL 0.00
- Stochastic Oscillator
- ACOG 0.00
- ANL 0.00
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.